Month: September 2024

REGULATED INFORMATIONThe interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section ‘Financial reports’. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report, the original French version will prevail.   Mont-Saint-Guibert, Belgium, 30 September 2024, 7am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today publishes its business update for the first half, ended 30 June 2024, prepared...

On 27.09.2024 EfTEN Paemurru OÜ, a subsidiary of the EfTEN Real Estate Fund AS, signed a contract under law of obligation with Teearu Arenduse OÜ, a member of the RESTATE group, for the acquisition of a property located on Paemurru tee 3, Laabi village, Harju County, Harku Municipality, near Tallinn.    In cooperation with Eventus Ehitus OÜ, the fund will construct an ICONFIT production, trade and warehouse building on the property. Eventus Ehitus OÜ started construction in July 2024, and completion of the building is planned by the end of April 2025. The investment is financed from the fund’s equity and from the loan agreement to be signed with AS SEB Pank. Completion of the purchase transaction is planned by the end of this year at the latest. Total investment of the fund will be 5.9 million euros plus VAT.   The tenant of the...

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic coughAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2024 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2024, and provided a corporate update. “During the first half, we achieved major milestones with the launch of Neurosterix with a series A financing of $63m led by Perceptive Advisors and the...

Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific expertise to guide the company’s strategic direction, this also signals Dr. Langer’s strong belief in the company’s mission and potential. Dr. Langer is a world-renowned scientist, entrepreneur, and biotechnology pioneer. His groundbreaking work in drug delivery systems and tissue engineering has earned him numerous awards and recognition, including the...

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a convertible note subscription agreement with its largest shareholder Gregory George (“Investor”) for issue, at its sole discretion, up to US$50.0 million (A$72.7 million) convertible notes on approval by the United States Food and Drug Administration (FDA) of Mesoblast’s lead product candidate Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD). The funding is available at Mesoblast’s option and will enable the Company to seamlessly implement its go-to-market commercial strategy. Mesoblast anticipates a decision prior to or on the FDA’s Prescription Drug User Fee Act...

OSLO, Norway, 29 September 2024 – Ensurge Micropower (OSE: ENSU, and OTCQB: ENMPY) (“Ensurge” or the “Company”) Terje Rogne, the chair of Ensurge Micropower ASA, will conduct a Webcast on Tuesday 1 October 2024 at 11:00 CEST.  The Webcast will be hosted by Arctic Securities. To join the Webcast please register on https://forms.office.com/e/7FExCD5ptD and a webcast link will be provided. It will be possible to ask questions during the presentation by using the Q&A tool embedded in the webcast.  About Ensurge Micropower Ensurge is Energizing Innovation(TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense...

Subsea 7 S.A. has received notification of transaction(s) in its shares by a primary insider. Please see the attached form for details. This information is pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.AttachmentCSSF Jean Cahuzac filing 8467 September 2024

SHANGHAI, Sept. 29, 2024 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced that it has entered into definitive agreements for investment in NIO Holding Co., Ltd., a PRC subsidiary in which it holds 92.1% controlling equity interest (“NIO China”), with Hefei Jianheng New Energy Automobile Investment Fund Partnership (Limited Partnership), Anhui Provincial Emerging Industry Investment Co., Ltd. and CS Capital Co., Ltd. (collectively, the “Strategic Investors”), pursuant to which the Strategic Investors will invest an aggregate of RMB3.3 billion in cash (the “Strategic Investment Amount”) to subscribe for newly issued shares of NIO China. Concurrently, NIO will invest an aggregate of RMB10 billion in cash...

Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that has failed, or the patient is...